

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
	Stakeholders raised concerns that there is inequality in access to current standards of care for people who have recurrent malignant ascites. This means some people with recurrent malignant ascites receive paracentesis as a hospital inpatient, whereas some NHS providers offer this as a day clinic procedure. People with recurrent malignant ascites are nearing end-of life and should have minimal medical appointments.
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
	The committee will consider the equalities issues presented. However, treatment availability based on geographical location is outside of the remit of a NICE technology appraisal.
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
	No changes have been made to the scope.

Health Technology Evaluation: Scoping

Equality impact assessment for the Health Technology Evaluation of catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

Issue date: October 2025

1 of 2

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No changes have been made to the stakeholder list.

Approved by Associate Director (name): Ross Dent

Date: 22/10/2025